Before joining Sloning, Mr Merry has held several executive positions in the field of sales and marketing with companies such as Applied Biosystems, Millipore, or Qiagen, where he was vice president of genomic services.
Mr Merry said: “This is a completely new selling experience: Sloning’s technology of creating gene mutant libraries is elegantly simple, yet so powerful, there is effectively no competition. Customers appreciate the libraries’ superior quality and their capacity to reduce screening effort.
“In addition, the fee for service business model saves customers from any licensing or royalty issues. I am proud to be part of this venture that is about to change the way people do protein engineering.”